Lantern Pharma extends share repurchase program to July 31, 2022; $3.6M remaining authorization.

Lantern Pharma Inc.

Board extended existing share repurchase program through July 31, 2022, with $7M total authorization.
Since Nov 2021, 475,157 shares repurchased for ~$3.4M; $3.6M remaining as of March 21, 2022.
Company had $70.7M cash, equivalents, and marketable securities as of Dec 31, 2021.
Repurchases may occur on open market or privately; program may be suspended at any time.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.